Skip to content

Study · Animal study (in vivo) · mouse · 2019

25 results

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide.

Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA

Physiological reports1 Oct 2019Cited by 38 (Europe PMC)

PMID31565870 (opens in a new tab)PMCIDPMC6766518 (opens in a new tab)DOI10.14814/phy2.14225 (opens in a new tab)PepBankPUB-31565870
Download PDFPubMedAsk about this study
Jump to 25 results

Summary

Teriparatide and abaloparatide are parathyroid hormone receptor 1 (PTHR1) analogs with unexplained differential efficacy for the treatment of osteoporosis. Therefore, we compared the effects of abaloparatide and teriparatide on bone structure, turnover, and levels of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG). Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days. Femurs and spines were examined by microcomputed tomography scanning and serum levels of bone turnover markers, RANKL, and OPG, were measured by ELISA. Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses. However, only abaloparatide exhibited a significant increase (13%) in trabecular thickness at 20 µg/kg/day dose. Femoral cortical evaluation showed that abaloparatide caused a greater dose-dependent increase in cortical thickness than teriparatide. Both teriparatide and abaloparatide increased lumbar 5 vertebral trabecular connectivity but had no or modest effect on other indices. Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio. Furthermore, PTHR1 signaling was compared in cells treated with 0-100 nmol/L analog. Interestingly, abaloparatide had a markedly lower EC50 for cAMP formation (2.3-fold) and β-arrestin recruitment (1.6-fold) than teriparatide. Therefore, abaloparatide-improved efficacy can be attributed to enhanced bone formation and cortical structure, reduced RANKL/OPG ratio, and amplified Gs-cAMP and β-arrestin signaling.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study25

25 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide increased distal femoral fractional trabecular bone volume similarly to teriparatide.

    In plain wordsIn mice, abaloparatide increased the fraction of femoral spongy bone versus vehicle, similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseDistal femoral fractional trabecular bone volume
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased distal femoral fractional trabecular bone volume similarly to abaloparatide.

    In plain wordsIn mice, teriparatide increased the fraction of femoral spongy bone versus vehicle, similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDistal femoral fractional trabecular bone volume
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide increased distal femoral trabecular connectivity similarly to teriparatide.

    In plain wordsIn mice, abaloparatide increased connections within femoral spongy bone versus vehicle, similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseDistal femoral trabecular connectivity
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased distal femoral trabecular connectivity similarly to abaloparatide.

    In plain wordsIn mice, teriparatide increased connections within femoral spongy bone versus vehicle, similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDistal femoral trabecular connectivity
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide increased distal femoral trabecular number similarly to teriparatide.

    In plain wordsIn mice, abaloparatide increased the number of femoral bone struts versus vehicle, similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseDistal femoral trabecular number
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased distal femoral trabecular number similarly to abaloparatide.

    In plain wordsIn mice, teriparatide increased the number of femoral bone struts versus vehicle, similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDistal femoral trabecular number
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide reduced the structure model index similarly to teriparatide.

    In plain wordsIn mice, abaloparatide reduced the bone structure model index versus vehicle, similarly to teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseStructure model index
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide reduced the structure model index similarly to abaloparatide.

    In plain wordsIn mice, teriparatide reduced the bone structure model index versus vehicle, similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseStructure model index
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both analogs similarly increased the distal femoral fractional trabecular bone volume, connectivity, and number, and reduced the structure model index (SMI) at 20-80 µg/kg/day doses.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide significantly increased trabecular thickness at the lowest tested dose.

    In plain wordsIn mice, abaloparatide increased bone strut thickness compared with vehicle at the lowest tested dose.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular thickness
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Measurements

    Trabecular thickness increase
    13%
    20 µg/kg/day

    Source sentences

    Summary
    However, only abaloparatide exhibited a significant increase (13%) in trabecular thickness at 20 µg/kg/day dose.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide did not significantly increase trabecular thickness at the lowest tested dose.

    In plain wordsIn mice, teriparatide did not significantly increase bone strut thickness compared with vehicle at the lowest tested dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular thickness
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    However, only abaloparatide exhibited a significant increase (13%) in trabecular thickness at 20 µg/kg/day dose.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide caused a greater dose-dependent increase in femoral cortical thickness than teriparatide.

    In plain wordsIn mice, abaloparatide increased femoral outer bone thickness more than teriparatide as dose increased.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseFemoral cortical thickness
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Femoral cortical evaluation showed that abaloparatide caused a greater dose-dependent increase in cortical thickness than teriparatide.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide produced a smaller dose-dependent increase in femoral cortical thickness than abaloparatide.

    In plain wordsIn mice, teriparatide increased femoral outer bone thickness less than abaloparatide as dose increased.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFemoral cortical thickness
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Femoral cortical evaluation showed that abaloparatide caused a greater dose-dependent increase in cortical thickness than teriparatide.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide increased lumbar vertebral trabecular connectivity.

    In plain wordsIn mice, abaloparatide increased connections within spinal spongy bone compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLumbar vertebral trabecular connectivity
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both teriparatide and abaloparatide increased lumbar 5 vertebral trabecular connectivity but had no or modest effect on other indices.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide increased lumbar vertebral trabecular connectivity.

    In plain wordsIn mice, teriparatide increased connections within spinal spongy bone compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar vertebral trabecular connectivity
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both teriparatide and abaloparatide increased lumbar 5 vertebral trabecular connectivity but had no or modest effect on other indices.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide had no or modest effects on other lumbar vertebral indices.

    In plain wordsIn mice, abaloparatide had no or small effects on other spinal bone measures compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    MixedOther lumbar vertebral indices
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both teriparatide and abaloparatide increased lumbar 5 vertebral trabecular connectivity but had no or modest effect on other indices.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide had no or modest effects on other lumbar vertebral indices.

    In plain wordsIn mice, teriparatide had no or small effects on other spinal bone measures compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedOther lumbar vertebral indices
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Both teriparatide and abaloparatide increased lumbar 5 vertebral trabecular connectivity but had no or modest effect on other indices.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide promoted greater P1NP elevation than teriparatide.

    In plain wordsIn mice, abaloparatide increased the bone formation marker P1NP more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseSerum P1NP
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide promoted less P1NP elevation than abaloparatide.

    In plain wordsIn mice, teriparatide increased the bone formation marker P1NP less than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum P1NP
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide promoted greater tartrate-resistant acid phosphatase 5b elevation than teriparatide.

    In plain wordsIn mice, abaloparatide increased the bone resorption marker more than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTartrate-resistant acid phosphatase 5b
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  20. 20AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, teriparatide promoted less tartrate-resistant acid phosphatase 5b elevation than abaloparatide.

    In plain wordsIn mice, teriparatide increased the bone resorption marker less than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTartrate-resistant acid phosphatase 5b
    Study

    mousen: not reported in source

    Wild-type female mice
    Comparator
    Abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  21. 21AnimalAnimal study (in vivo)Efficacy outcome

    In female mice, abaloparatide lowered the RANKL/OPG ratio.

    In plain wordsIn mice, abaloparatide lowered the ratio of two bone turnover signals.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseRANKL/OPG ratio
    Study

    mousen: not reported in source

    Wild-type female mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20-80 µg/kg/day · injection · 30 daysAs given in this study (mouse).

    Source sentences

    Summary
    Biochemical analysis demonstrated that abaloparatide promoted greater elevation of procollagen type 1 intact N-terminal propeptide, a bone formation marker, and tartrate-resistant acid phosphatase 5b levels, a bone resorption marker, and lowered the RANKL/OPG ratio.
    1 context sentence
    Summary · context
    Wild-type (WT) female mice were injected daily with vehicle or 20-80 µg/kg/day of teriparatide or abaloparatide for 30 days.
  22. 22LabIn vitro (cells)Activity measurement

    In cells, abaloparatide had a lower EC50 for cAMP formation than teriparatide.

    In plain wordsIn cells, abaloparatide required less drug for half-maximal cAMP production than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreasecAMP formation EC50
    Study

    n: not reported in source

    Comparator
    Teriparatide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    0-100 nmol/LAs given in this study.

    Measurements

    EC50 reduction
    2.3 fold
    abaloparatide versus teriparatide

    Source sentences

    Summary
    Interestingly, abaloparatide had a markedly lower EC50 for cAMP formation (2.3-fold) and β-arrestin recruitment (1.6-fold) than teriparatide.
    1 context sentence
    Summary · context
    Furthermore, PTHR1 signaling was compared in cells treated with 0-100 nmol/L analog.
  23. 23LabIn vitro (cells)Activity measurement

    In cells, teriparatide had a higher EC50 for cAMP formation than abaloparatide.

    In plain wordsIn cells, teriparatide required more drug for half-maximal cAMP production than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasecAMP formation EC50
    Study

    n: not reported in source

    Comparator
    Abaloparatide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    0-100 nmol/LAs given in this study.

    Source sentences

    Summary
    Interestingly, abaloparatide had a markedly lower EC50 for cAMP formation (2.3-fold) and β-arrestin recruitment (1.6-fold) than teriparatide.
    1 context sentence
    Summary · context
    Furthermore, PTHR1 signaling was compared in cells treated with 0-100 nmol/L analog.
  24. 24LabIn vitro (cells)Activity measurement

    In cells, abaloparatide had a lower EC50 for β-arrestin recruitment than teriparatide.

    In plain wordsIn cells, abaloparatide required less drug for half-maximal β-arrestin recruitment than teriparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Decreaseβ-arrestin recruitment EC50
    Study

    n: not reported in source

    Comparator
    Teriparatide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    0-100 nmol/LAs given in this study.

    Measurements

    EC50 reduction
    1.6 fold
    abaloparatide versus teriparatide

    Source sentences

    Summary
    Interestingly, abaloparatide had a markedly lower EC50 for cAMP formation (2.3-fold) and β-arrestin recruitment (1.6-fold) than teriparatide.
    1 context sentence
    Summary · context
    Furthermore, PTHR1 signaling was compared in cells treated with 0-100 nmol/L analog.
  25. 25LabIn vitro (cells)Activity measurement

    In cells, teriparatide had a higher EC50 for β-arrestin recruitment than abaloparatide.

    In plain wordsIn cells, teriparatide required more drug for half-maximal β-arrestin recruitment than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Increaseβ-arrestin recruitment EC50
    Study

    n: not reported in source

    Comparator
    Abaloparatide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    0-100 nmol/LAs given in this study.

    Source sentences

    Summary
    Interestingly, abaloparatide had a markedly lower EC50 for cAMP formation (2.3-fold) and β-arrestin recruitment (1.6-fold) than teriparatide.
    1 context sentence
    Summary · context
    Furthermore, PTHR1 signaling was compared in cells treated with 0-100 nmol/L analog.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.